Precision Antithyroid Therapy (feasibility)
Research type
Research Study
Full title
Precision Antithyroid Therapy (feasibility study)
IRAS ID
283570
Contact name
David J Smith
Contact email
Sponsor organisation
University of Birmingham
Clinicaltrials.gov Identifier
ERN_20-0985, University of Birmingham ethical review number
Duration of Study in the UK
0 years, 2 months, 11 days
Research summary
Hyperthyroidism is a common condition affecting approximately 1 million people in the UK. The thyroids (glands located in the neck) produce too much of certain hormones called ‘T3’ and ‘T4’. This condition can occur for a number of reasons, including growths and the immune system being over-active. If these hormones aren't controlled properly, they can have serious effects such as heart failure or osteoporosis.
Doctors treat hyperthyroidism with drugs to reduce how much hormone is made. The amount of drug needed is hard to predict, so patients have to return for tests and changes to their dose, often several times. This is inconvenient and expensive. It can be bad for the patients if their hormones are too high or too low.
We will solve this problem by developing an app to enable doctors to predict the best dose. The app will take into account hormone levels at the beginning and early stages of treatment, age, sex, and weight.
The app will then say what is likely to happen to hormone levels in response to different doses, in order to decide what the best treatment is. The maths inside the app will be based on patient records from Queen Elizabeth Hospital Birmingham.
REC name
N/A
REC reference
N/A